Topic 20: Multiple Sclerosis Flashcards

1
Q

What is the prevalence of multiple sclerosis around the world?

A

causes decrease toward the equator

due to: European background, lack of sun exposure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the most common age of onset of MS?

A

ages 15-25

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the prevalence of pediatric MS?

A

6% of MS in total

3 to 10% of MS patients onset </= age 18

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the prevalence of MS based on gender?

A

3:1, female:male

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is relapsing-remitting progression of MS?

A

symptoms then back to baseline

or symptoms that decrease but don’t go fully back to baseline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is secondary progression of MS?

A

around 70% of the time

no fluctuations, just steady progression?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the Expanded Disability Status Scale (EDSS)?

A

evaluating the motor changes, not cognitive ones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the pathology of MS?

A

many lesions in the white and gray matter

lesions damage the nerve fibers and tracts

location of lesion causes symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the relationship between MS and myelination?

A

demyelination, remyelination, axonal transection

decreased axonal density in MS plaques

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the causes of MS?

A

genes

environment: infections (EBV, Mono, could bring things to the surface), smoking, sun exposure, sodium (activates the immune system)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the genetic contribution to multiple sclerosis risk?

A

no Mendelian relationship

genome wide association studies: HLA or MSC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can EAE be produced in animals?

A

can be produced by myelin-specific T cells

mice injected with myelin basic protein and complete Frund’s adjuvant develop demyelinating disease (EAE)

the disease is mediated by myelin basic protein-specific T cells

disease can be transmitted by transfer of T cells from affected animal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the immunology of EAE?

A
  1. inject MBP
  2. in a pool of naïve T cells there will be a MBP-recognizing cell
  3. MBP-specific T cells cause antigen presentation
  4. there is an expansion of MBP-reactive T cells and they enter the CNS
  5. these cells are reactivated in the CNS, products produce CNS pathology
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is the process of EAE a model of molecular mimicry?

A
  1. virus with molecular similarity to myelin protein (e.g. MBP) interacts with a pool of naïve cells that contains virus-recognizing cells and MBP-recognizing cells
  2. there is antigen presentation of virus to naïve T cells
  3. this causes expansion of virus specific T cells trying to get rid of viruses, and expansion of cross-relative MBP-specific T cells which cause accidental activation which can cause alkaline reaction
  4. these cells enter the CNS, recognize MBP, and initiate inflammatory damage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What do naïve CD4 T cell differentiate into?

A

differentiate into Th1, Th2, Th17, and T regulatory cells

different path based on environment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is MS pathogenesis based on B lymphocytes?

A

antigen presentation

Breg dysfunction

antibody production

ectopic germinal centers

cytokine activation of astrocytes/microglia

17
Q

What kind of inflammation is seen in MS plaques?

A

peri-vascular inflammation

18
Q

What is the pathogenesis of MS in neurons?

A

astrocyte activation

neuro-axonal degeneration

microglia activation

energy failure

glutamate excitotoxicity

inflammation

ionic imbalance and increased sodium levels

demyelination

activate microglia, axonal death, swelling of axons, demyelination

19
Q

What is immune dependent neurodegeneration in MS?

A

immune dependent, immune system is causing damage, microglia, astrocyte, and B cell caused

20
Q

What is immune independent neurodegeneration in MS?

A

microglia: mtDNA mutation, energy deficiencies, ROS/RNS, mitochondrial injury

astrocyte: demyelination, Fe3+, oxidative stress

B cell: influx of Ca++, glutamate excitotoxicity, ionic imbalance

immune independent due to the swelling, even if inflammation stopped these pathways will continue

21
Q

What is the brain atrophy in MS?

A

enlarged ventricles

damage to white and grey matter

22
Q

What are clinical manifestations of MS?

A

symptoms in almost any area

ocular: blurred vision, diplopia

cerebellar: ataxic walk, vertigo, nystagmus

autonomic: urinary incontinence, sexual disorders

motor: reduced strength and activity, muscle spasms, muscle weakness and loss of strength

sensory manifestations: tuning fork, sensory changes, hypesthesia, progressive sensory loss

23
Q

What is fatigue?

A

a feeling of physical tiredness and lack of energy distinct from sadness or weakness

very difficult for patients or caregivers to describe

severe in up to 74% of patients, worst symptom of the disease in 50-60% of patients

24
Q

What is bladder overactivity?

A

urgency, frequency, urge incontinence

25
What is bladder inefficiency?
incomplete emptying, residual, urine
26
What is detrusor-sphincter dyssynergia?
co-contraction of bladder and urethral sphincter
27
How many MS patients are affected by bladder dysfunction?
about 75%
28
What is persistent neurogenic pain?
hard to treat burning dysesthesia of the limbs and/or trunk attributed to disruption of the spinothalamic pathway usually within the spinal cord
29
What is paroxysmal neurogenic pain?
trigeminal neuralgia episodes of excruciating facial pain
30
How many MS patients are affected by pain?
about 40-50%
31
What are treatments of MS in the immune system?
existing treatments primarily target the inflammatory component of MS
32
What are treatments of MS in the CNS?
there is a need for novel agents that directly target protection and repair of the CNS as well as targeting inflammation
33
What are different therapy options for MS?
traditional injections: beta-interferons, glatiramer acetate oral therapies: dimethyl fumarate (Tecfidera), fingolimod (Gilenya), teriflunomide (Abagio), cladribine Autologous stem cell transplant (experimental) chemotherapies: mitoxantrone, cyclophosphamine monoclonal antibodies: natalizumab (Tysabri), alemtuzumab (Lemtrada), ocrelizumab
34
What are traditional immunomodulatory therapies for treatment of MS?
in the 1990's interferon (IFN)beta1b: 2 preparations, betaseron, extavia IFNbeta1a: (sc) and (im) variations glatriamer acetate (GA): copaxone
35
How does interferon-beta act to treat MS?
interferon-beta acts through the interferon-beta receptor and inhibits antigen presentation and T cell activation reduced the activation of autoreactive T cells decreases pro-inflammatory Th1 cytokines
36
How does GA act to treat MS?
GA is presented as an antigen and generates GA-specific T cells of Th2 bias GA peptide --> GA specific Th2 cells
37
How does dimethyl fumarate treat MS?
dimethyl fumarate activates Nrf2 Nrf2 activates protective response against neurotoxic insult, this increases cell tissue and cytoprotection Nrf2 ant-inflammatory response, decreases inflammation and tissue damage
38
How does S1P treat MS?
the signal mediated through S1P regulated the exit of lymphocytes from lymph nodes